Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project

Pere Ginès; Maja Thiele; Isabel Graupera; Miquel Serra-Burriel; Robert J. de Knegt; Frank Lammert; Laurent Castera; Marko Korenjak; Patrick S. Kamath; Ivica Grgurević; Salvatore Piano; Núria Fabrellas; Anita Arslanow; Aleksander Krag

doi:10.1038/s41591-023-02265-z

Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project

Pere Ginès, Maja Thiele, Isabel Graupera, Miquel Serra-Burriel, Robert J. de Knegt, Frank Lammert, Laurent Castera, Marko Korenjak, Patrick S. Kamath, Ivica Grgurević, Salvatore Piano, Núria Fabrellas, Anita Arslanow, Aleksander Krag

Gastroenterology and Hepatology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	774-775
Number of pages	2
Journal	Nature Medicine
Volume	29
Issue number	4
DOIs	https://doi.org/10.1038/s41591-023-02265-z
State	Published - Apr 2023

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/s41591-023-02265-z

Cite this

@article{f0904eb70f6d4c28aef0d65bf461c62f,

title = "Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project",

author = "Pere Gin{\`e}s and Maja Thiele and Isabel Graupera and Miquel Serra-Burriel and {de Knegt}, {Robert J.} and Frank Lammert and Laurent Castera and Marko Korenjak and Kamath, {Patrick S.} and Ivica Grgurevi{\'c} and Salvatore Piano and N{\'u}ria Fabrellas and Anita Arslanow and Aleksander Krag",

note = "Funding Information: In this context, the goal of the LIVERSCREEN project is to provide an easy-to-use, cost-effective screening program for the early detection of liver fibrosis using non-invasive markers. These include serological tests and vibration-controlled transient elastography (VCTE). The screening program will be implemented and evaluated in different European countries to investigate its efficacy in the diagnosis of liver fibrosis as well as its potential long-term impact on morbidity and mortality due to cirrhosis and liver cancer. The project is funded by the European Commission H2020 program under the call SC1-BHC-30-2019, “Towards risk-based screening strategies for non-communicable diseases” (project no. 847989). The consortium comprises 20 partners from 10 European countries, mainly academic partners but also private companies, as well as patient and physician associations, including the European Liver Patient Association and EASL. The main bodies of the Consortium are the General Assembly and the Project Management Team. The General Assembly consists of one member for each partner and is responsible for approving the Consortium{\textquoteright}s rules and strategic decisions. The Project Management Team is the executive body responsible tasked with ensuring that the project achieves the proposed goals, monitoring its implementation and proposing major strategic decisions. There is also an external Advisory Board composed of physicians with specific expertise in liver disease. Funding Information: The LiverScreen project is funded by European Union{\textquoteright}s Horizon2020 programme under grant agreement no. 847989. ",

year = "2023",

month = apr,

doi = "10.1038/s41591-023-02265-z",

language = "English (US)",

volume = "29",

pages = "774--775",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Screening for fibrosis to diagnose liver diseases early

T2 - the LIVERSCREEN project

AU - Ginès, Pere

AU - Thiele, Maja

AU - Graupera, Isabel

AU - Serra-Burriel, Miquel

AU - de Knegt, Robert J.

AU - Lammert, Frank

AU - Castera, Laurent

AU - Korenjak, Marko

AU - Kamath, Patrick S.

AU - Grgurević, Ivica

AU - Piano, Salvatore

AU - Fabrellas, Núria

AU - Arslanow, Anita

AU - Krag, Aleksander

N1 - Funding Information: In this context, the goal of the LIVERSCREEN project is to provide an easy-to-use, cost-effective screening program for the early detection of liver fibrosis using non-invasive markers. These include serological tests and vibration-controlled transient elastography (VCTE). The screening program will be implemented and evaluated in different European countries to investigate its efficacy in the diagnosis of liver fibrosis as well as its potential long-term impact on morbidity and mortality due to cirrhosis and liver cancer. The project is funded by the European Commission H2020 program under the call SC1-BHC-30-2019, “Towards risk-based screening strategies for non-communicable diseases” (project no. 847989). The consortium comprises 20 partners from 10 European countries, mainly academic partners but also private companies, as well as patient and physician associations, including the European Liver Patient Association and EASL. The main bodies of the Consortium are the General Assembly and the Project Management Team. The General Assembly consists of one member for each partner and is responsible for approving the Consortium’s rules and strategic decisions. The Project Management Team is the executive body responsible tasked with ensuring that the project achieves the proposed goals, monitoring its implementation and proposing major strategic decisions. There is also an external Advisory Board composed of physicians with specific expertise in liver disease. Funding Information: The LiverScreen project is funded by European Union’s Horizon2020 programme under grant agreement no. 847989.

PY - 2023/4

Y1 - 2023/4

UR - http://www.scopus.com/inward/record.url?scp=85151405898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151405898&partnerID=8YFLogxK

U2 - 10.1038/s41591-023-02265-z

DO - 10.1038/s41591-023-02265-z

M3 - Letter

C2 - 37002369

AN - SCOPUS:85151405898

SN - 1078-8956

VL - 29

SP - 774

EP - 775

JO - Nature Medicine

JF - Nature Medicine

IS - 4

ER -

Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this